POP Biotechnologies

POP Biotechnologies, Inc. is a biotechnology firm established in 2016 and headquartered in Buffalo, New York. The company originated from research conducted at the University at Buffalo, co-founded by Jonathan Smyth and Kevin Carter. Their work centers on a proprietary platform technology known as Porous-Organosilica Particles (POP-abel), which serves as a versatile delivery system for vaccines and therapeutics. This technology aims to improve the stability, delivery, and immune response of complex biological products. The core of their business is the development and out-licensing of this technology to pharmaceutical and biotechnology partners for use in creating more effective vaccines and therapies.

The company's primary product, the POP-abel platform, is engineered to overcome challenges associated with developing vaccines against complex pathogens. By encapsulating vaccine antigens within these silica-based nanoparticles, the platform can enhance their stability, allowing for storage and distribution without the need for refrigeration, a significant logistical advantage in global health settings. Furthermore, the technology has demonstrated the ability to elicit a stronger and more durable immune response compared to traditional vaccine adjuvants. One of POP Biotechnologies' notable achievements is its collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to develop a universal influenza vaccine candidate, leveraging the POP-abel platform to present multiple flu antigens simultaneously. This partnership has progressed to clinical trials, with a Phase I study initiated to evaluate the safety and immunogenicity of the vaccine candidate.

POP Biotechnologies' business model focuses on strategic partnerships and licensing agreements. The company collaborates with larger pharmaceutical firms, providing its platform as a component for their vaccine and drug development pipelines. This B2B approach allows them to participate in the lucrative biopharmaceutical market without undertaking the full cost and risk of late-stage clinical development and commercialization. Their client base consists of entities engaged in the creation of vaccines for infectious diseases and cancer immunotherapies. Through its efforts, the company has secured multiple grants and awards, including significant funding from the National Institutes of Health (NIH), to advance its technology platform. Keywords: vaccine delivery, nanotechnology, biopharmaceutical, licensing, platform technology, adjuvant, immunogenicity, universal flu vaccine, nanoparticle, drug formulation